— Fundamental Stock Analysis and Report Card
Located in Acton, MA, US. Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Revenue, earnings and profitability.
Strong revenue growth and earnings can attract investors, driving the stock price up. Profitability indicates the company's efficiency and sustainability, which impacts investor confidence. Poor performance in these areas can lead to a decrease in stock price.
Revenue History
Earnings History
Margins
Income & Cash Flow analysis.
An income statement shows what a company earned and spent over a period — revenue at the top, costs and expenses in between, and net income at the bottom. A cash flow statement tracks the actual cash moving in and out, across operations, investing, and financing. Read together, they show whether reported earnings are backed by real cash.
Q1 2026 Total ($) | Q1 2026 Margin (%) | |
|---|---|---|
| Revenue | 761.7m +192.7m +33.9% | |
| Gross Income | 529.1m +120.1m +29.4% | 69% -2.4pp -3.4% |
| EBITDA | 153.9m +74.9m +94.8% | 20% +6.3pp +45.5% |
| Operating Income | 122.1m +33.3m +37.5% | 16% +0.4pp +2.7% |
| Net Income | 91.1m +55.7m +157.3% | 12% +5.7pp +92.2% |
| Earnings Per Share | 1.30 +0.8 +160.0% | |
| Operating Cash Flow | 113.8m +50.0m +78.4% | 15% +3.7pp +33.2% |
| Free Cash Flow | 86.0m +34.5m +67.0% | 11% +2.2pp +24.7% |
| Research & Development | 89.7m +30.1m +50.5% | 12% +1.3pp +12.4% |